Abstract 387P
Background
PD-1/PD-L1 inhibitor plus chemotherapy have shown tolerability and significant clinical benefits in pts with advanced TNBC. Antiangiogenic agent could remodel tumor blood vessels and increase the response to immune-checkpoint inhibitors (ICIs). AK105, an anti-PD-1 antibody, can effectively prevents PD-1 from binding to PD-L1 and PD-L2, and avoid immune evasion of tumor cells. Anlotinib is a novel antiangiogenic, multi-target tyrosine kinase inhibitor. This investigator initiated trial aims to investigate the efficacy and safety of AK105, anlotinib combined with nab-P as a first-line therapy in pts with advanced TNBC.
Methods
In this multicenter, prospective, single arm, phase 2 study, eligible pts were female aged 18-75 years, with ECOG PS 0-1, who had locally advanced or recurrent/metastatic triple-negative breast cancer. Eligible pts were treated with intravenous AK105 (200 mg on d1), oral anlotinib (12 mg once daily on d1-d14) and intravenous nab-P (125 mg/m2 on d1 and d8). The triplet combination regimen repeated every 21 days until disease progression, death or intolerable toxicity. The primary endpoint is ORR, and the secondary endpoints are DCR, PFS, OS and safety.
Results
From July 2022 to March 2024, 33 patients have been enrolled in this study. Median follow-up was 6.54 months (95% CI 2.68-11.43). Of all the patients whose efficacy could be evaluated (26/33), 1 (3.85%) patient achieved CR; 20 (76.92%), 4 (15.38%) and 1 (3.85%) patients got PR, SD and PD, respectively. ORR was 80.77 % (95% CI 60.65-93.45) and DCR was 96.15% (95% CI 80.36-99.90). The overall mPFS was 11.14 months (95% CI 8.34-18.04), the mOS have not reached. The most common AEs were grade 1 or 2. The grade 3 AEs (incidence ≥ 10%) included were neutropenia (33.33%), leukopenia (12.12%) and elevated AST (12.12%). There were two case of grade 4 neutropenia and one case of grade 4 hypertriglyceridemia. One death (from hepatitis) was considered by the investigators to be related to the trial regimen.
Conclusions
The combination of AK105, anlotinib and nab-P showed better treatment response and tolerable toxicity in the treatment of first-line patients with TNBC.
Clinical trial identification
NCT05244993.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chiatai Tianqing.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15